REGENXBIO Inc. (RGNX)
NASDAQ: RGNX
· Real-Time Price · USD
9.87
0.26 (2.71%)
At close: May 01, 2025, 3:59 PM
9.14
-7.30%
After-hours: May 01, 2025, 05:46 PM EDT
2.71% (1D)
| Bid | 9.14 |
| Market Cap | 494.4M |
| Revenue (ttm) | 83.33M |
| Net Income (ttm) | -227.1M |
| EPS (ttm) | -4.59 |
| PE Ratio (ttm) | -2.15 |
| Forward PE | -8.99 |
| Analyst | Buy |
| Ask | 9.99 |
| Volume | 527,951 |
| Avg. Volume (20D) | 946,480 |
| Open | 9.60 |
| Previous Close | 9.61 |
| Day's Range | 9.36 - 9.93 |
| 52-Week Range | 5.04 - 17.52 |
| Beta | 1.26 |
About RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, wh...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 17, 2015
Employees 353
Stock Exchange NASDAQ
Ticker Symbol RGNX
Website https://www.regenxbio.com
Analyst Forecast
According to 7 analyst ratings, the average rating for RGNX stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 204.11% from the latest price.
Stock ForecastsNext Earnings Release
REGENXBIO Inc. is scheduled to release its earnings on May 12, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+8.97%
REGENXBIO shares are trading higher after the comp...
Unlock content with
Pro Subscription
2 months ago
-7.1%
Regenxbio shares are trading lower after Goldman Sachs downgraded the stock from Buy to Neutral and cut its price target from $38 to $14.
